HIV-1 RNA levels and the development of clinical disease

AIDS

Volumn 10, Issue 8, 1996, Pages 859-865

  Phillips, Andrew N ^a,e   Eron, Joseph J ^b   Bartlett, John A ^c   Rubin, Marc ^d   Johnson, Judy ^e   Price, Sharon ^b   Self, Pamela ^b   Hill, Andrew M ^c  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

^e GLAXOSMITHKLINE   (United States)

Author keywords

AIDS; CD4 lymphocyte count; HIV RNA; Viral load

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; LAMIVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

EID: 0029899473     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199607000-00009     Document Type: Article

References (45)

1. PiatakM, Saag MS, Yang LC, et al:. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1995, 259:1749-1754.
2. Ho DD, Moudgil T, Alam M: Quantitation of HIV-1 in the blood of infected persons. N Engl J Med 1989, 321:1621-1625.
3. Coombs RW, Collier AC, Allin J-P, et al.: Plasma viraemia in HIV infection. N Engl J Med 1989, 321:1626-1631.
4. Semple M, Loveday C, Weller I, Tedder R: Direct measurement of viraemia in patients infected with HIV-1 and its relationship to disease progression and zidovudine therapy. J Med Vir0l 1991, 35:38-45.
5. Loveday C, HilJ A: Prediction of progression to AIDS with serum HIV-1 RNA and CD4 count, lancet 1995, 345:790-791.
6. Henrard DR, Phillips JF, Muenz LR, et al.: Natural history of HIV-1 cell-free viraemia. JAMA 1995,274:554-558.
7. Mellors JW, Kingsley LA, Rinaldo CR, et aJ.: Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995, 122:573-579.
8. Hogervorst E, Jurriaans S, de Wolf F, et al.: Predictors for non-and slow progression in HIV-1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. I Infect Dis 1995, 171:811-821.
9. Molina J-M, Perchai F, Chevret S, et al.: Quantification of HIV-1 virus load under zidovudine therapy in patients with symptomatic HIV infection: relation to disease progression. AIDS 1994, 8:27-33.
10. Verhofstede C, Reniers S, Van Wanzeele F, Plum J: Evaluation of proviral copy number and plasma RNA level as early indicators of progression in HIV-1 infection: correlation with virological and immunological markers of disease. AIDS 1994, 8:1421-1427.
11. Ruffault A, Michelet C, Jacquelinet C, et al.: The prognostic value of plasma viraemia in HIV-infected patients under AZT treatment: a two-year follow-up study. J Acquir Immune Defic Syndf 1995, 9:243-248.
12. O'Brien WA, Hartigan PM, Martin D, et al.: The relationship of treatment-induced changes in plasma HIV-1 RNA and CD4+ lymphocyte count to progression to AIDS in The Department of Veterans Affairs Zidovudine Study. N Engl J Med 1996, 334:426-431.
13. Lafeuillade A, Tamalet C, Pellegrino P, de Micco PH, Vignoli C, Quilichini R: Correlation between surrogate markers, viral load and disease progression in HIV-1 infection. J Acquir Immune Defic Syndr 1994, 7:1028-1033.
14. Katzenstein TL, Pedersen C, Nielsen C, Lundgren JD, Jakobsen PH, Gerstoft J: Longitudinal serum HIV RNA quantification: correlation to viral phenotype at seroconversion and clinical outcome. AIDS 1996, 10:167-174.
15. Schnittman SM, Greenhouse JJ, Psallidopoulos MC, et al.: Increasing viral burden in CD4+T cells from patients with HIV infection reflects rapidly progressive immunosuppression and clinical disease. Ann Intern Med 1990, 113:438-443.
16. Lu W, Grassi F, Tourani J-M, et al.: High concentration of PBMCs harbouring infectious virus correlates with rapid progression of HIV-1 related diseases. J Infect Dis 1993, 168:1165-1168.
17. Lee T-H, Sheppard HW, Reis M, Dondero D, Osmond D, Busch MP: Circulating HIV-1 infected cell burden from seroconversion to AIDS: importance of postseroconversion viral load on disease course. J Acquir Immune Defic Syndr 1994, 7:3 81 -3 88.
18. Connor Rl, Mohri H, Cao Y, Ho DD: Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in HIV-1 infected individuals. / Virol 1993, 67:1772-1777.
19. Michael NL, Vahey M, Burke DS, Redfield RR: Viral DNA and mRNA expression correlate with the stage of HIV-1 infection in humans: evidence for viral replication in all stages of HIV disease. J Virol 1992, 66:310-316.
20. Schlechter MT, Neumann PW, Weaver MS, ef ai: Low HIV-1 proviral DNA burden detected'by negative polymerase chain reaction in seropositive individuals correlates with slower disease progression. AIDS 1991, 5:373-379.
21. Venet A, Lu W, Beldjord K, Andrieu JM: Correlation between CD4 cell counts and cellular and plasma viral load in HIV-1 seropositive individuals. AIDS 1991, 5:283-288.
22. Mathez D, Paul D, de Belivovsky C, et al.: Productive human immunodeficiency virus infection levels correlate with AIDSrelated manifestations in the patient. Proc Natl Acad Sci USA 1990,87:7438-7442.
23. Holidniy M, Katzenstein DA, Sengupta S, et al.: Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. J Infect Dis 1991, 163:862-866.
24. Lefrere JJ, Mariotti M, Wattel E, et al.: Towards a new predictor of AIDS progression through the quantitation of HIV-1 DNA copies by PCR in HIV-infected individuals. Br J Haematol 1992, 82:467-471.
25. Wood R, Dong H, Katzenstein DA, Merigan TC: Quantification and comparison of HIV-1 proviral load in peripheral blood mononuclear cells and isolated CD4+ T cells. J Acquir Immune Defic Syndr 1993, 6:237-240.
26. Bagnarelli P, Menzo S, Valenza A, et al.: Molecular profile of human immunodeficiency virus type 1 infection in symptomless patients and in patients with AIDS. J Virol 1992, 66:7328-7335.
27. Ferre F, Marchese A, Duffy PC, et al.: Quantitation of HIV viral burden by PCR in HIV seropositive Navy personnel representing Walter Reed stages 1 to 6. AIDS Res Hum Retroviruses 1992, 8:269-275.
28. Cupta P, Kingsley L, Armstrong J, Ding M, Cottrill M, Rinaldo C: Enhanced expression of human immunodeficiency virus type 1 correlates with the development of AIDS. Virology 1993, 196:586-595.
29. Saksela K, Stevens CE, Rubenstein P, Taylor PE, Baltimore D: HIV-1 messenger RNA in peripheral blood mononuclear cells as an early marker of risk for progression to AIDS. Ann Intern Med 1995,123:641-648.
30. Phillips AN, Sabin CA, Mocroft A: Serum HIV-1 RNA and routine patient monitoring [letter], lancet 1995, 345:1441.
31. Eron JJ, Benoit SL, Jemsek J, et al.: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995, 333:1662-1669.
32. 3: a randomized, double-blind, multicenter, controlled trial. Ann Intern Med 1996 (in press).
33. Centers for Disease Control: 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41 (RR-17):1-19.
34. Phillips AN, Sabin CA, Elford J, Bofill M, Janossy G, Lee CA: AIDS risk in recent and long-standing HIV-infected people with similar CD4 lymphocyte counts. Am J Epidemiol 1993,138:870-878.
35. Phillips AN, Pezzotti P, Cozzi Lepri A, Rezza G: CD4 lymphocyte count as a determinant of the time from HIV seroconversion to AIDS and death from AIDS: evidence from the Italian Serocon-version Study. AIDS 1994, 8:1299-1305.
36. Spijkerman IJB, Koot M, Prins M, et al.: Lower prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users compared with homosexual men. AIDS 1995,9:1085-1092.
37. Mocroft A, Sabin CA, Phillips AN: Lower prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users relative to homosexual men. AIDS 1996,10:344-345.
38. Phillips AN: Studies of prognostic markers in HIV infection: implications for pathogenesis. AIDS 1992, 6:1391-1394.
39. Altman DG, De Stavola BL: Practical problems in fitting a pro-portional hazards model to data with updated measurements of the covariates. Stat Med 1994,13:301-341.
40. Holodniy M, Mole L, Winters M, Merigan TC: Diurnal and short-term stability of viral load as measured by gene amplification. J Acquir Immune Defic Syndr 1994, 7:363-368.
41. Ho DD: HIV-1 viraemia and influenza [letter]. Lancet 1992, 339:1549.
42. Yerly S, Wunderli W, Wyler ÇA, et al.: Influenza immunization of HIV-1 infected patients does not increase HIV-1 viral load [letter]. AIDS 1994, 8:1503-1504.
43. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in HIV-1 infection. Nature 1995, 373:117-126.
44. Ho DD, et al.: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
45. Phillips AN, Davey Smith G: How independent are 'independent' effects? Relative risk estimation when correlated exposures are measured imprecisely. J Clin Epidemiol 1991, 44:1223-1231.